https://cts.businesswire.com/ct/CT?id=smartlink&url=https://www.businesswire.com/news/home/20230731194052/en/AVM-Biotechnology-Announces-Twenty-Eight-28-Solid-Tumor-and-Blood-Cancer-Patients-have-been-Treated-with-Immunomodulatory-AVM0703-through-Expanded-AccessCompassionate-Use-Programs&esheet=53514448&newsitemid=20230809463056&lan=en-US&anchor=AVM Biotechnology Announces Twenty-Eight (28) Solid Tumor and Blood Cancer Patients have been Treated with Immunomodulatory AVM0703 through Expanded Access/Compassionate Use Programs | Business Wire&index=4&md5=be55c5e79d6780e1489f8c5c255a8160